文献速递临床试验与 GCP基础与转化研究

0.09%环孢素联合强脉冲光治疗症状性隐形眼镜佩戴者干眼症:假对照随机临床试验研究方案

Combination of 0.09% cyclosporine and intense pulsed light (IPL) therapy for the treatment of dry eye disease in symptomatic contact lens wearers: study protocol for a sham-controlled randomized clinical trial.
PubMed 文献 · Trials · 2026-02-07

主要结局为问卷症状评分,次要结局包括泪膜稳定性、泪河高度、渗透压、睑板腺萎缩和眼表染色,并评估安全性。

要点

  • 针对软性隐形眼镜佩戴者的干眼不适,探索环孢素联合强脉冲光的协同效果。
  • 采用随机假对照设计,主要结局为症状问卷评分,次要结局涵盖泪膜和眼表指标。
  • 安全性评估包括视力、眼压和不良事件问卷,为临床推广提供依据。

核心结论

  • 该研究旨在验证纳米胶束环孢素联合强脉冲光能否改善软性隐形眼镜佩戴者的舒适度。
  • 不适是隐形眼镜佩戴者 dropout 的主要原因,联合治疗可能提供新的干预手段。

研究设计与样本

  • 所有受试者先使用0.09%环孢素每日两次,8周后随机接受三次强脉冲光或假治疗。

主要发现

  • 原文未报告研究结果,仅描述研究方案和计划评估的结局指标。

关键数值与推荐

  • 主要结局为问卷症状评分,采用t检验比较。
  • 次要结局包括泪膜稳定性(泪膜上和镜片上)、泪河高度、渗透压、睑板腺萎缩和眼表染色,采用混合效应模型分析。
  • 安全性通过视力、眼压和不良事件问卷评估。

临床怎么用

  • 若结果阳性,可为眼科专业人员提供联合治疗工具,改善隐形眼镜佩戴体验。
  • 研究方案强调针对整个泪膜的治疗策略,可能影响未来干眼管理思路。

局限性

  • 原文未报告研究的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Discomfort while using soft contact lenses is a major concern in eyecare, and it is strongly linked to dry eye. Many new dry eye therapies have not yet been studied on contact lens users. Cyclosporine is a pharmaceutical agent that has recently been re-engineered in a nanomicellar drop. Intense pulsed light is a potent treatment for meibomian gland dysfunction. Very little data exists on the effects of these treatments, and they have never been tested in combination. The aim of this study was to test the effects of the combination of nanomicellar cyclosporine and intense pulsed light on the symptoms and signs of soft contact lens users. METHODS: Forty-four symptomatic soft contact lens users will be recruited from a primary care optometry practice. They will receive cyclosporine 0.09% to use twice daily, and, after 8 weeks, they will be randomized to receive three sessions of intense pulsed light or a sham. Primary outcome will be the symptom score using a questionnaire, and secondary outcomes will include tear film stability measurements (both on the tear film and over contact lenses), tear meniscus height, osmolarity, meibomian gland atrophy, and ocular surface staining. Safety will be assessed by measuring visual acuity, intra-ocular pressure, and an adverse effects questionnaire. Questionnaire scores will be compared using a t-test, while other measurements will be analyzed using mixed-model effects. DISCUSSION: This study aims to test whether a combination of novel dry eye treatments that target the whole tear film improves comfort while wearing contact lenses. Discomfort is a major issue that leads to drop out. The results of this study could provide eyecare professionals with additional tools to help their patients and could open the discussion on future solutions to improve contact lens users' experience. TRIAL REGISTRATION: ClinicalTrials.gov NCT06392438 , registered on April 23rd, 2024.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Lortie-Milner E, Michaud L, Dubois MF, et al. Combination of 0.09% cyclosporine and intense pulsed light (IPL) therapy for the treatment of dry eye disease in symptomatic contact lens wearers: study protocol for a sham-controlled randomized clinical trial. Trials. 2026. PMID: 41654845. doi:10.1186/s13063-026-09521-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。